Waypoint Bio is a biotechnology company pioneering novel cell therapies for solid tumors using its proprietary spatial pooled screening technology and lab-in-the-loop approach. Since launching in 2024 the company has raised $14.5 million in funding from leading biotech and tech investors and assembled a scientific advisory board of drug R&D and cancer experts. While the company is currently focused on designing novel, solid tumor cell therapies for cancer, its technology has the potential for more drug discovery applications, including Treg therapies for autoimmune diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/28/24 | $14,500,000 | Seed |
Fifty Years Hummingbird Ventures  Recode Ventures | undisclosed |
